Tetranectin as a Potential Biomarker in Heart Failure with Ejection Fraction >45%: A Prospective Cohort Study

1 MCDONAGH TA, METRA M, ADAMO M, GARDNER RS, BAUMBACH A, BOHM M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Eur Heart J. 2021;42(36):3599–3726. MCDONAGHTA METRAM ADAMOM GARDNERRS BAUMBACHA BOHMM 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Eur Heart J 2021 42 36 3599 3726 Search in Google Scholar

2 MCDONAGH TA, METRA M, ADAMO M, GARDNER RS, BAUMBACH A, BOHM M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Eur Heart J. 2023;44(37):3627–3639. MCDONAGHTA METRAM ADAMOM GARDNERRS BAUMBACHA BOHMM 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Eur Heart J 2023 44 37 3627 3639 Search in Google Scholar

3 PONIKOWSKI P, ANKER SD, ALHABIB KF, COWIE MR, FORCE TL, HU S, et al. Heart failure: preventing disease and death worldwide ESC Heart Fail. 2014;1(1):4–25. PONIKOWSKIP ANKERSD ALHABIBKF COWIEMR FORCETL HUS Heart failure: preventing disease and death worldwide ESC Heart Fail 2014 1 1 4 25 Search in Google Scholar

4 SAVARESE G, BECHER PM, LUND LH, SEFEROVIC P, ROSANO GMC, COATS AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology Cardiovasc Res. 2023;118(17):3272–3287. SAVARESEG BECHERPM LUNDLH SEFEROVICP ROSANOGMC COATSAJS Global burden of heart failure: a comprehensive and updated review of epidemiology Cardiovasc Res 2023 118 17 3272 3287 Search in Google Scholar

5 GROENEWEGEN A, RUTTEN FH, MOSTERD A, HOES AW. Epidemiology of heart failure Eur J Heart Fail. 2020;22(8):1342–1356. GROENEWEGENA RUTTENFH MOSTERDA HOESAW Epidemiology of heart failure Eur J Heart Fail 2020 22 8 1342 1356 Search in Google Scholar

6 VIRANI SS, ALONSO A, BENJAMIN EJ, BITTENCOURT MS, CALLAWAY CW, CARSON AP, et al. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association Circulation. 2020;141(9):e139–e596. VIRANISS ALONSOA BENJAMINEJ BITTENCOURTMS CALLAWAYCW CARSONAP Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association Circulation 2020 141 9 e139 e596 Search in Google Scholar

7 BOZKURT B, COATS AJS, TSUTSUI H, ABDELHAMID CM, ADAMOPOULOS S, ALBERT N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure Eur J Heart Fail. 2021;23(3):352–380. BOZKURTB COATSAJS TSUTSUIH ABDELHAMIDCM ADAMOPOULOSS ALBERTN Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure Eur J Heart Fail 2021 23 3 352 380 Search in Google Scholar

8 LAM CSP, VOORS AA, DE BOER RA, SOLOMON SD, VAN VELDHUISEN DJ. Heart failure with preserved ejection fraction: from mechanisms to therapies Eur Heart J. 2018;39(30):2780–2792. LAMCSP VOORSAA DE BOERRA SOLOMONSD VAN VELDHUISENDJ Heart failure with preserved ejection fraction: from mechanisms to therapies Eur Heart J 2018 39 30 2780 2792 Search in Google Scholar

9 KOMAJDA M, LAM CS. Heart failure with preserved ejection fraction: a clinical dilemma Eur Heart J. 2014;35(16):1022–1032. KOMAJDAM LAMCS Heart failure with preserved ejection fraction: a clinical dilemma Eur Heart J 2014 35 16 1022 1032 Search in Google Scholar

10 DUNLAY SM, ROGER VL, REDFIELD MM. Epidemiology of heart failure with preserved ejection fraction Nat Rev Cardiol. 2017;14(10):591–602. DUNLAYSM ROGERVL REDFIELDMM Epidemiology of heart failure with preserved ejection fraction Nat Rev Cardiol 2017 14 10 591 602 Search in Google Scholar

11. PAULUS WJ, TSCHOPE C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 62(4):263–271. PAULUSWJ TSCHOPEC A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation J Am Coll Cardiol 62 4 263 271 Search in Google Scholar

12. OWAN TE, HODGE DO, HERGES RM, JACOBSEN SJ, ROGER VL, REDFIELD MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 355(3):251–259. OWANTE HODGEDO HERGESRM JACOBSENSJ ROGERVL REDFIELDMM Trends in prevalence and outcome of heart failure with preserved ejection fraction N Engl J Med 355 3 251 259 Search in Google Scholar

13. REDFIELD MM. Heart failure with preserved ejection fraction. N Engl J Med. 375(19):1868–1877. REDFIELDMM Heart failure with preserved ejection fraction N Engl J Med 375 19 1868 1877 Search in Google Scholar

14. ZILE MR, BAICU CF, IKONOMIDIS JS, STROUD RE, NIETERT PJ, BRADSHAW AD, et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 131(14):1247–1259. ZILEMR BAICUCF IKONOMIDISJS STROUDRE NIETERTPJ BRADSHAWAD Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin Circulation 131 14 1247 1259 Search in Google Scholar

15. SHAH AM, SHAH SJ, ANAND IS, SWEITZER NK, O’MEARA E, HEITNER JF, et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circ Heart Fail. 7(1):104–115. SHAHAM SHAHSJ ANANDIS SWEITZERNK O’MEARAE HEITNERJF Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial Circ Heart Fail 7 1 104 115 Search in Google Scholar

16. WESTERMANN D, KASNER M, STEENDIJK P, SPILLMANN F, RIAD A, WEITMANN K, et al. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation. 117(16):2051–2060. WESTERMANND KASNERM STEENDIJKP SPILLMANNF RIADA WEITMANNK Role of left ventricular stiffness in heart failure with normal ejection fraction Circulation 117 16 2051 2060 Search in Google Scholar

17. VAN HEEREBEEK L, BORBELY A, NIESSEN HW, BRONZWAER JG, VAN DER VELDEN J, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 113(16):1966–1973. VAN HEEREBEEKL BORBELYA NIESSENHW BRONZWAERJG VAN DER VELDENJ Myocardial structure and function differ in systolic and diastolic heart failure Circulation 113 16 1966 1973 Search in Google Scholar

18. WROBEL-NOWICKA K, WOJCIECHOWSKA C, JACHEC W, ZALEWSKA M, ROMUK E. The role of oxidative stress and inflammatory parameters in heart failure. Medicina (Kaunas). 60(5):760. WROBEL-NOWICKAK WOJCIECHOWSKAC JACHECW ZALEWSKAM ROMUKE The role of oxidative stress and inflammatory parameters in heart failure Medicina (Kaunas) 60 5 760 Search in Google Scholar

19. MAISEL AS, DURAN JM, WETTERSTEN N. Natriuretic peptides in heart failure: Atrial and B-type natriuretic peptides. Heart Fail Clin. 14(1):13–25. MAISELAS DURANJM WETTERSTENN Natriuretic peptides in heart failure: Atrial and B-type natriuretic peptides Heart Fail Clin 14 1 13 25 Search in Google Scholar

20. TANASE DM, RADU S, AL SHURBAJI S, BAROI GL, FLORIDA COSTEA C, TURLIUC MD, et al. Natriuretic peptides in heart failure with preserved left ventricular ejection fraction: from molecular evidences to clinical implications. Int J Mol Sci. 20(11):2629. TANASEDM RADUS AL SHURBAJIS BAROIGL FLORIDA COSTEAC TURLIUCMD Natriuretic peptides in heart failure with preserved left ventricular ejection fraction: from molecular evidences to clinical implications Int J Mol Sci 20 11 2629 Search in Google Scholar

21. LI P, ZHAO H, ZHANG J, et al. Similarities and differences between HFmrEF and HFpEF. Front Cardiovasc Med. 8:678614. LIP ZHAOH ZHANGJ Similarities and differences between HFmrEF and HFpEF Front Cardiovasc Med 8 678614 Search in Google Scholar

22. CLEMMENSEN I, PETERSEN LC, KLUFT C. Purification and characterization of a novel, oligomeric, plasminogen kringle 4 binding protein from human plasma: tetranectin. Eur J Biochem. 156(2):327–333. CLEMMENSENI PETERSENLC KLUFTC Purification and characterization of a novel, oligomeric, plasminogen kringle 4 binding protein from human plasma: tetranectin Eur J Biochem 156 2 327 333 Search in Google Scholar

23. KOPEVA KV, GRAKOVA EV, SHILOV SN, BEREZIKOVA EN, BOBYLEVA ET, TEPLYAKOV AT. Tetranectin as a potential novel prognostic biomarker in anthracycline-related cardiac dysfunction. Heart Vessels. 38(10):1256–1266. KOPEVAKV GRAKOVAEV SHILOVSN BEREZIKOVAEN BOBYLEVAET TEPLYAKOVAT Tetranectin as a potential novel prognostic biomarker in anthracycline-related cardiac dysfunction Heart Vessels 38 10 1256 1266 Search in Google Scholar

24. MCDONALD K, GLEZEVA N, COLLIER P, O’REILLY J, O’CONNELL E, TEA I, et al. Tetranectin, a potential novel diagnostic biomarker of heart failure, is expressed within the myocardium and associates with cardiac fibrosis. Sci Rep. 10(1):7507. MCDONALDK GLEZEVAN COLLIERP O’REILLYJ O’CONNELLE TEAI Tetranectin, a potential novel diagnostic biomarker of heart failure, is expressed within the myocardium and associates with cardiac fibrosis Sci Rep 10 1 7507 Search in Google Scholar

25. BORLAUG BA, PAULUS WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 32(6):670–679. BORLAUGBA PAULUSWJ Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment Eur Heart J 32 6 670 679 Search in Google Scholar

26. PIESKE B, TSCHOPE C, DE BOER RA, FRASER AG, ANKER SD, DONAL E, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 40(40):3297–3317. PIESKEB TSCHOPEC DE BOERRA FRASERAG ANKERSD DONALE How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) Eur Heart J 40 40 3297 3317 Search in Google Scholar

27. IRAM S, RAHMAN S, CHOI I, KIM J. Insight into the function of tetranectin in human diseases: a review and prospects for tetranectin-targeted disease treatment. Heliyon. 10(1):e23512. IRAMS RAHMANS CHOII KIMJ Insight into the function of tetranectin in human diseases: a review and prospects for tetranectin-targeted disease treatment Heliyon 10 1 e23512 Search in Google Scholar

28. HO JE, LYASS A, COURCHESNE P, CHEN G, LIU C, YIN X, et al. Protein biomarkers of cardiovascular disease and mortality in the community. J Am Heart Assoc. 7(14):e008108. HOJE LYASSA COURCHESNEP CHENG LIUC YINX Protein biomarkers of cardiovascular disease and mortality in the community J Am Heart Assoc 7 14 e008108 Search in Google Scholar

29. WANG TJ, WOLLERT KC, LARSON MG, COGLIANESE E, MCCABE EL, CHENG S, et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation. 126(13):1596–1604. WANGTJ WOLLERTKC LARSONMG COGLIANESEE MCCABEEL CHENGS Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study Circulation 126 13 1596 1604 Search in Google Scholar

30. GILSTRAP LG, WANG TJ. Biomarkers and cardiovascular risk assessment for primary prevention: an update. Clin Chem. 58(1):72–82. GILSTRAPLG WANGTJ Biomarkers and cardiovascular risk assessment for primary prevention: an update Clin Chem 58 1 72 82 Search in Google Scholar

31. SAVARESE G, STOLFO D, SINAGRA G, LUND LH. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol. 19(2):100–116. SAVARESEG STOLFOD SINAGRAG LUNDLH Heart failure with mid-range or mildly reduced ejection fraction Nat Rev Cardiol 19 2 100 116 Search in Google Scholar

32. VEDIN O, LAM CSP, KOH AS, BENSON L, TENG THK, TAY WT, et al. Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study. Circ Heart Fail. 10(6):e003875. VEDINO LAMCSP KOHAS BENSONL TENGTHK TAYWT Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study Circ Heart Fail 10 6 e003875 Search in Google Scholar